MRK · 10-Q · 2026Q3 · Full report
Manufacturing Network Optimization
Merck & Co., Inc. · 2026-11-04 · Importance 17 · Surprise 24 · In source text
Merck plans to align the geography of its global manufacturing footprint with customers and changes in its business, while continuing to optimize its manufacturing network. Manufacturing actions under the 2025 program are expected to be substantially completed by the end of 2029. The 2024 program also targets the Human Health network as the pipeline shifts to new modalities and the Animal Health network to improve supply reliability and efficiency. Actions under the 2024 program are expected to be substantially completed by the end of 2031.
Key facts
- The 2024 Restructuring Program is expected to yield cumulative annual net cost savings of approximately $750 million by the end of 2031. source
- The 2024 Restructuring Program is expected to be substantially completed by the end of 2031, with approximately $4.0 billion of cumulative pretax costs. source
- Approximately 50% of the 2024 Restructuring Program's cumulative pretax costs will be non-cash, primarily accelerated depreciation of facilities to be closed or divested. source
- The 2024 Restructuring Program was approved in January 2024 to optimize Human Health and Animal Health global manufacturing networks. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | -11.1% | The 2024 Restructuring Program is expected to be substantially completed by the end of 2031, with approximately $4.0 billion of cumulative… |
| operating_income | positive | committed | +3.5% | The 2024 Restructuring Program is expected to yield cumulative annual net cost savings of approximately $750 million by the end of 2031. |